Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis
Authors Jung J, Kong M, Hong SE
Received 18 June 2014
Accepted for publication 24 July 2014
Published 26 September 2014 Volume 2014:7 Pages 1769—1775
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Dr Faris Farassati
Jinhong Jung, Moonkyoo Kong, Seong Eon Hong
Department of Radiation Oncology, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, Republic of Korea
Background: The purpose of this study was to evaluate clinical outcomes of conventional fractionated helical tomotherapy in patients with small to medium hepatocellular carcinomas (HCCs) without portal vein tumor thrombosis.
Methods: Patients with up to four HCC lesions not treatable by surgery or percutaneous ablative therapies, <10 cm in the longest diameter, and no evidence of major vascular invasion were included. From January 2008 to January 2013, 20 patients with 33 tumors met the eligibility criteria and received definitive or salvage helical tomotherapy. The most commonly prescribed dose fractionation schedule was a total dose of 50 Gy with a daily dose of 2.5 Gy. Treatment response, survival, and radiation-induced toxicities were retrospectively reviewed.
Results: The median follow-up period after radiotherapy for all patients was 24.9 (range 7.8–79.2) months. Objective responses (complete response or partial response) occurred in 30 of 33 lesions (90.9%). Eight (24.2%) lesions showed local recurrence and the actuarial local control rate at 2 years was 69.5%. Intrahepatic recurrence-free survival and overall survival rates at 2 years were 45.7% and 71.1%, respectively. Age, Child–Pugh class, tumor response, local recurrence status, and intrahepatic recurrence status were significantly associated with overall survival on univariate analysis. Among these parameters, only local recurrence status showed marginal statistical significance on multivariate analysis (P=0.068). The overall survival rate at 2 years was 50% for patients who experienced local recurrence, but 87.5% for those who did not. No patient experienced grade 2 or greater general or gastrointestinal toxicity. There were no cases of radiation-induced liver disease.
Conclusion: Conventional fractionated helical tomotherapy for patients with less than four small to medium HCCs without portal vein tumor thrombosis yielded favorable local control and overall survival without severe complications.
Keywords: hepatocellular carcinoma, conventional fractionated radiotherapy, helical tomotherapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]